Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
On February 4, 2011, several directors and managers purchased ordinary shares through the reinvestment of dividends within Individual Savings Accounts (ISAs). The transaction price was £11.72 per ordinary share. The specific share counts acquired were:
- Mr A P Witty: 17 shares
- Mr J S Heslop: 9 shares
- Mr S M Bicknell: 65 shares
- Mr E J Gray: 8 shares
- Mr D S Redfern: 8 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure required under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Confirm the total number of shares held by the named directors following these dividend reinvestments.
- Verify the market price of GSK ordinary shares on February 4, 2011, to contextualize the £11.72 transaction price.
- Review subsequent filings for any further changes in director shareholdings.